The 10-day moving average for LIEN crossed bearishly below the 50-day moving average on October 08, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 67%.
The Momentum Indicator moved below the 0 level on October 22, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on LIEN as a result. In 73 of 113 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 65%.
LIEN moved below its 50-day moving average on September 30, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LIEN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 57%.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where LIEN's RSI Indicator exited the oversold zone, 18 of 24 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 75%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 17 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +1.27% 3-day Advance, the price is estimated to grow further. Considering data from situations where LIEN advanced for three days, in 111 of 199 cases, the price rose further within the following month. The odds of a continued upward trend are 56%.
LIEN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 59 of 96 cases where LIEN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 61%.
The Tickeron SMR rating for this company is 52 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 58 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating steady price growth. LIEN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.686) is normal, around the industry mean (2.404). P/E Ratio (6.540) is within average values for comparable stocks, (-3.413). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.319). Dividend Yield (0.150) settles around the average of (0.272) among similar stocks. P/S Ratio (5.811) is also within normal values, averaging (15.798).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LIEN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 82, placing this stock worse than average.
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where TXMD declined for three days, in 271 of 311 cases, the price declined further within the following month. The odds of a continued downward trend are 87%.
The Momentum Indicator moved below the 0 level on October 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TXMD as a result. In 92 of 110 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.
TXMD moved below its 50-day moving average on September 25, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for TXMD crossed bearishly below the 50-day moving average on October 01, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 19 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 74%.
The 50-day moving average for TXMD moved below the 200-day moving average on October 05, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
The Aroon Indicator for TXMD entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator entered the oversold zone -- be on the watch for TXMD's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 50 of 76 cases where TXMD's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 66%.
Following a +2.15% 3-day Advance, the price is estimated to grow further. Considering data from situations where TXMD advanced for three days, in 145 of 205 cases, the price rose further within the following month. The odds of a continued upward trend are 71%.
TXMD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of 5 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.789) is normal, around the industry mean (10.407). P/E Ratio (-92.500) is within average values for comparable stocks, (-6.173). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.037) among similar stocks. P/S Ratio (7.740) is also within normal values, averaging (178.797).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 55 (best 1 - 100 worst), indicating steady price growth. TXMD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 91 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TXMD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
TXMD | ||
|---|---|---|
OUTLOOK RATING 1..100 | 55 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 5 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 91 | |
PRICE GROWTH RATING 1..100 | 55 | |
P/E GROWTH RATING 1..100 | 98 | |
SEASONALITY SCORE 1..100 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| LIEN | TXMD | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 75% | 1 day ago 80% |
| Stochastic ODDS (%) | 1 day ago 57% | 1 day ago 66% |
| Momentum ODDS (%) | 1 day ago 65% | 1 day ago 84% |
| MACD ODDS (%) | N/A | N/A |
| TrendWeek ODDS (%) | 1 day ago 58% | 1 day ago 86% |
| TrendMonth ODDS (%) | 1 day ago 61% | 1 day ago 84% |
| Advances ODDS (%) | 18 days ago 56% | 2 days ago 71% |
| Declines ODDS (%) | 4 days ago 57% | 4 days ago 87% |
| BollingerBands ODDS (%) | 1 day ago 66% | 1 day ago 62% |
| Aroon ODDS (%) | 1 day ago 61% | 1 day ago 84% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
LIEN’s FA Score shows that 0 FA rating(s) are green while TXMD’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
LIEN’s TA Score shows that 6 TA indicator(s) are bullish while TXMD’s TA Score has 4 bullish TA indicator(s).
LIEN (@Investment Managers) experienced а +0.66% price change this week, while TXMD (@Pharmaceuticals: Generic) price change was -3.55% for the same time period.
The average weekly price growth across all stocks in the @Investment Managers industry was -1.40%. For the same industry, the average monthly price growth was -5.36%, and the average quarterly price growth was -0.89%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -2.94%. For the same industry, the average monthly price growth was -9.84%, and the average quarterly price growth was +9.53%.
LIEN is expected to report earnings on Nov 12, 2026.
TXMD is expected to report earnings on Nov 11, 2026.
Investment Managers manage financial assets and other investments of clients. Management includes designing a short- or long-term strategy for buying/holding and selling of portfolio holdings. It can also include tax services and other aspects of financial planning as well. While it is perceived that the industry is faced with growing competition from robo-advisors/digital platforms and passive/ index-tracking funds, many investors still find value in actively managed in-person services that investment management companies often emphasize on. At the same time, many wealth managers are also incorporating digital initiatives/low cost options in addition to their in-person customized services. Their main sources of revenues are fees as a percentage of assets under management, in addition to a certain portion of clients’ gains from asset appreciation. BlackRock, Inc., Blackstone Group Inc and Brookfield Asset Management are some of the major investment management companies.
@Pharmaceuticals: Generic (-2.94% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
A.I.dvisor indicates that over the last year, LIEN has been loosely correlated with TXMD. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if LIEN jumps, then TXMD could also see price increases.
| Ticker / NAME | Correlation To LIEN | 1D Price Change % | ||
|---|---|---|---|---|
| LIEN | 100% | -0.11% | ||
| TXMD - LIEN | 36% Loosely correlated | -2.63% | ||
| CGBD - LIEN | 26% Poorly correlated | +1.98% | ||
| KBDC - LIEN | 24% Poorly correlated | +2.49% | ||
| CSWC - LIEN | 21% Poorly correlated | +0.04% | ||
| MAAS - LIEN | 21% Poorly correlated | -5.45% | ||
More | ||||
A.I.dvisor indicates that over the last year, TXMD has been loosely correlated with LIEN. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if TXMD jumps, then LIEN could also see price increases.
| Ticker / NAME | Correlation To TXMD | 1D Price Change % | ||
|---|---|---|---|---|
| TXMD | 100% | -2.63% | ||
| LIEN - TXMD | 36% Loosely correlated | -0.11% | ||
| IMCC - TXMD | 24% Poorly correlated | -22.29% | ||
| ACB - TXMD | 23% Poorly correlated | +0.25% | ||
| BCRX - TXMD | 22% Poorly correlated | +0.39% | ||
| SBFM - TXMD | 22% Poorly correlated | -22.47% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| MSTI | 19.89 | N/A | N/A |
| Madison Short Term Strategic Income ETF (MSTI) | |||
| CHW | 7.94 | N/A | N/A |
| Calamos Global Dynamic Income Fund | |||
| GRX | 10.02 | -0.06 | -0.60% |
| Gabelli Healthcare & Wellness Trust (The) | |||
| VTHR | 335.94 | -3.84 | -1.13% |
| Vanguard Russell 3000 ETF (VTHR) | |||
| SPCL | 12.75 | -1.64 | -11.40% |
| Defiance Pure Space Daily 2X Strategy ETF (SPCL) | |||